A treatment comparison of carfilzomib, dexamethasone and daratumumab to daratumumab and bortezomib
A treatment comparison of carfilzomib, dexamethasone and daratumumab to daratumumab and bortezomib
Real-world evidence of the use of carfilzomib to refractory to lenalidomide patients
Real-world evidence of the use of carfilzomib among multiple myeloma patients across 10 European countries and Israel
2020 updates in treating NTRK fusion cancer
PARP inhibitors for prostate cancer: What oncology PAs should know
ESMO 2020: New developments in the treatment of lung cancer
SABCS 2020: Conference roundup
PRWCC: Disease burden impacts outcomes in paediatric and young adult B-Cell ALL after commercial tisagenlecleucel
Researchers trace the origin of blood cancer to early childhood, decades before diagnosis
Risk profiling of relapsed/refractory diffuse large B-cell lymphoma patients by measuring circulating tumour DNA
ASH 2020: Immunotherapy in relapsed/refractory multiple myeloma
Survival analysis of newly diagnosed transplant-eligible multiple myeloma patients in the randomised Forte trial